Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Impacts and effects of CAR T-cell therapy for pediatric ALL

Christina Peters • 29 Jun 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T Tisagenlecleucel

Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, discusses the use of tisagenlecleucel CAR T-cell therapy for relapsed/refractory children and young adults with acute lymphoblastic leukemia (ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christina Peters

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:05
FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
Christina Peters • 23 Apr 2023
0:55
The role of tisa-cel in the context of allogeneic transplantation in pediatric ALL
Christina Peters • 23 Apr 2023
1:03
Using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in B-ALL
Christina Peters • 23 Apr 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals